Medication info
Olviner Plus Tablet

Olviner Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Dae Hwa Pharmaceutical Co., Ltd.
Appearance
Round film-coated tablet of yellowish-red color
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201100887 · Approved 2011.02.24 · Insurance code 645603990

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is coadministered or when switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide alone and in patients with volume depletion or hyponatremia. In such cases, reduce the dose of hydrochlorothiazide to 12.5mg before coadministering olmesartan medoxomil. <Older adults> In older adults, start with the lowest dose and use caution when adjusting the dose, taking the patient's renal or cardiac function, comorbidities, and other concomitant medications into consideration. <Patients with renal failure> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal failure (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal failure, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic failure> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic failure.
Child dose
The safety and efficacy in children have not been established.

Ingredients

Manufacturer
Dae Hwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension for whom blood pressure control is difficult with monotherapy of either Olmesartan Medoxomil or Hydrochlorothiazide. The two components work together to effectively lower and control blood pressure. This helps to reduce the risk of cardiovascular complications due to hypertension and improve health.

How to take

Adult dose

Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is coadministered or when switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide alone and in patients with volume depletion or hyponatremia. In such cases, reduce the dose of hydrochlorothiazide to 12.5mg before coadministering olmesartan medoxomil. <Older adults> In older adults, start with the lowest dose and use caution when adjusting the dose, taking the patient's renal or cardiac function, comorbidities, and other concomitant medications into consideration. <Patients with renal failure> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal failure (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal failure, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic failure> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic failure.

Child dose

The safety and efficacy in children have not been established.

Precautions

This medication can cause severe harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to the components in this medication or those hypersensitive to certain diuretics, individuals with severe kidney or liver disease, and pregnant or breastfeeding women should not take this medication. Patients with low blood volume or low salt may experience hypotension, so careful observation and measures are needed before administration. For patients with severe heart failure or reduced kidney function, changes in kidney function may occur, necessitating regular blood tests. Patients with liver disease or certain heart conditions, and those with systemic lupus erythematosus should be cautious when taking this medication. This medication can cause skin reactions, so it is advisable to limit sun exposure, and any skin changes should be discussed with a doctor immediately. While taking this medicine, symptoms such as dizziness, headache, indigestion, and cough may occur, and if severe edema or an allergic reaction occurs, it should be stopped immediately and medical attention sought. This medication may interact with other antihypertensives, diuretics, potassium supplements, etc. If taking other medications, always consult a physician or pharmacist. Regularly check electrolyte levels in the blood to ensure balance of potassium, sodium, magnesium, etc. Care is needed when driving or operating machinery, particularly for the elderly or children, as dizziness may occur during use. In case of overdose, symptoms such as hypotension, palpitations, and electrolyte imbalance may appear, requiring prompt medical attention. Women who are pregnant, planning to become pregnant, or breastfeeding should consult medical personnel before taking this medication, and discontinuation or alternative treatments should be considered if necessary.

Side effects

Nausea, hyperuricemia, dizziness, upper respiratory tract infection, headache, urinary tract infection, chest pain, low back pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, elevated creatine phosphokinase, hyperglycemia, cough, rash, hematuria, facial edema, asthenia, angioedema, anaphylactic reaction, vomiting, rhabdomyolysis, acute renal failure, increased serum creatinine, hair loss, pruritus, urticaria, palpitations, hypercholesterolemia, hyperuricemia, arthralgia, arthritis, myalgia, chronic malabsorption syndrome, intestinal vascular edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, transient visual disturbance, jaundice, jaundice (intrahepatic cholestatic jaundice), hepatitis, acute cholecystitis, necrotizing vasculitis, interstitial pneumonia, pulmonary edema, dyspnea, malaise, nasal congestion, erectile dysfunction, exacerbation of systemic lupus erythematosus, hypercalcemia, muscle cramps, sensory abnormalities, weakness, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, loss of appetite, thirst, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, dry mouth, drowsiness, emotional blunting, restlessness, palpitations, angioedema, anaphylactic reaction, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, increased serum creatinine, hair loss, pruritus, urticaria, autoimmune hepatitis, hypertension, epistaxis, asthma, increased serum creatinine, epistaxis, asthma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a sealed container. The recommended storage temperature is between 1 and 25 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

Round film-coated tablet of yellowish-red color

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.